



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

7.

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/779,447	02/09/2001	Dipak K. Banerjee	P19850.p06	6690
24496	7590	09/29/2006	EXAMINER	
PATENT LAW OFFICES OF HEATH W. HOGLUND 256 ELEANOR ROOSEVELT STREET SAN JUAN, PR 00918				KRISHNAN, GANAPATHY
ART UNIT		PAPER NUMBER		
		1623		

DATE MAILED: 09/29/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

RECEIVED

SEP 29 2006

TECH CENTER 1600/290C

**BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES**

Application Number: 09/779,447

Filing Date: February 09, 2001

Appellant(s): BANERJEE ET AL.

Heath W. Hoglund
For Appellant

EXAMINER'S ANSWER

This is in response to the appeal brief filed April 11, 2006 appealing from the Office action
mailed May 17, 2004.

(1) Real Party in Interest

A statement identifying by name the real party in interest is contained in the brief.

(2) Related Appeals and Interferences

The examiner is not aware of any related appeals, interferences, or judicial proceedings which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

(3) Status of Claims

Claim1-8, 10-13, 15-17 and 19-92 been canceled.

(4) Status of Amendments After Final

The appellant's statement of the status of amendments after final rejection contained in the brief is correct.

(6) Grounds of Rejection to be Reviewed on Appeal

The appellant's statement of the grounds of rejection to be reviewed on appeal is correct.

(7) Claims Appendix

The copy of the appealed claims contained in the Appendix to the brief is correct.

(8) Evidence Relied Upon

Banerjee et al, Indian J. Biochem. and Biophysics, vol. 30(6), pp. 389-94, 1993.

Tiganis et al., Exp. Cell Research, vol. 198, pp. 191-200, 1992.

(9) Grounds of Rejection

The following ground(s) of rejection are applicable to the appealed claims:

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 9, 14 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Banerjee et al., Indian J. Biochem. Biophysics, vol. 30(6), pp. 389-94 (1993) and Tiganis et al., Exp. Cell Research, vol. 198, pp. 191-200 (1992).

Claims 9, 14 and 18 are drawn to a method for inhibiting angiogenesis comprising administering a pyrimidine nucleoside, wherein the nucleoside comprises N-acetylated glucosamine or comprises tunicamycin and functional derivatives thereof administered with daily and weekly dosages.

Banerjee teaches that angiogenesis comprises (1) endothelial cell proliferation and (2) differentiation into blood capillaries. Banerjee teaches the use of a pyrimidine nucleoside as an antiangiogenic agent as it teaches that the angiogenic process of capillary endothelial cell proliferation is linked to the synthesis of N-linked oligosaccharide chains which is inhibited by the pyrimidine nucleoside tunicamycin (which contains a linked glucosamine). Tiganis et al., further supports the recognition in the prior art of the inhibition of N-glycosylation by tunicamycin and the disruption of vascular proliferation or angiogenesis. Tiganis teaches that the inhibition of glycoproteins by tunicamycin impairs the cell adhesion and the functional properties of the endothelial lining of the blood vessels. Thus one of skill in the art would have a reasonable expectation of success that if tunicamycin is a potent inhibitor of N-glycosylation and that this inhibition disrupts component (1) of angiogenesis, there is clearly a reasonable expectation of success in the use of tunicamycin as an agent which would inhibit angiogenesis.

Banerjee does not specifically mention the functional derivatives of tunicamycin nor the timetable of administration to a patient; however, characteristics normally possessed by members of a homologous series are principally the same, chemists would in general know what to expect in adjacent members of homologs of known compounds. The test of patentability of a compound that is a homolog of a prior art compound is whether the claimed compound possesses beneficial characteristics which are unexpected and unobvious. One of skill in the art would have a reasonable expectation of success in the use of homologs of tunicamycin as antiangiogenic compounds given the efficacy of the parent compound. There is no data in the prior art nor the specification that presents some property of these homologs apart from that of the parent compound, chiefly the inhibition of angiogenesis. One of skill in the art would also have a reasonable expectation of success that a compound which inhibits angiogenesis would be beneficial in various disease states which may be disrupted by or thrive on the process of angiogenesis. Applicant's claims regarding the administration timetable of the known compound is not patentable given that one of skill in the art practicing the administration of any medical compound determines the optimum dosage for each patient, based on a variety of physical and metabolic factors.

It would have been *prima facie* obvious to a person of ordinary skill in the art at the time the invention was made to use a pyrimidine nucleoside such as tunicamycin to inhibit angiogenesis.

A person of ordinary skill in the art would have been motivated to use a pyrimidine nucleoside such as tunicamycin given the prior art's recognition of tunicamycin as an inhibitor of the pathway leading to the angiogenic process of capillary endothelial cell proliferation.

(10) Response to Argument

Applicant's primary argument is that the prior art discloses the in vitro application of tunicamycin to endothelial cells and angiogenesis, while the invention as claimed targets in vivo. Applicant's should note that the instant disclosure is solely based on in vitro data (emphasis added). Applicant has not presented any data demonstrating an in vivo use in the instant disclosure and the suggestion of a dosage does not demonstrate an in vivo use. While a demonstration of in vivo use in a disclosure is not absolutely required to support claims thereto, it is clear that applicant's disclosure uses in vitro data to support the inhibition of angiogenesis while contending that the same use of in vitro data in the prior art is not correlative. The recitation of specific dosage intervals represents a protocol for administering tunicamycin to achieve the same effect already recognized in the prior art wherein the claims to specific dosages and the time periods are based on in vitro data that was previously presented in the prior art.

One of skill in the art need not be certain of the efficacy of a compound to constitute a reasonable motivation to use the compound for an asserted utility. Using the rationale set forth in *In re Brana*, 51 F.3d 1560, the test as to whether an in vitro model provides sufficient correlation to an in vivo model is whether the “[in vitro] model represents a specific disease against which the claimed compounds are alleged to be effective”, *Brana*, 1565. As such, the in vitro data presented by Banerjee and Tiganis that use of the compound tunicamycin inhibits angiogenesis provides a reasonable correlation and motivation to use the compound in vivo.

As cited supra, banerjee teaches that angiogenesis comprises (1) endothelial cell proliferation and (2) differentiation into blood capillaries. Banerjee teaches the use of a pyrimidine nucleoside as an antiangiogenic agent as it teaches that the angiogenic process of

capillary endothelial cell proliferation is linked to the synthesis of N-linked oligosaccharide chains which is inhibited by the pyrimidine nucleoside tunicamycin (which contains a linked glucosamine). Banerjee teaches that protein N-glycosylation and angiogenesis are indeed interlined (p. 293, para 3); moreover, that tunicamycin inhibited N-glycosylation in control cells by 64% and those treated with isoproterenol (page 392, col. 1-col. 2). Thus Banerjee has recognized that tunicamycin is a potent N-glycosylation inhibitor, as such given the teachings by Banerjee that angiogenesis is linked to N-glycosylation, one of skill in the art would have a reasonable expectation of success in the use of tunicamycin to inhibit angiogenesis.

Applicant also asserts that Tiganis et (Tiganis) teaches away from the in vivo use of tunicamycin because of the adverse side effect of tunicamycin, wherein applicant cites page 199 of Tiganis. Prior to page 199, Tiganis cites on page 198, col. 2, paragraph 3, "tunicamycin inhibited the growth and was cytotoxic for dividing endothelial cells but did not inhibit the growth and was when tunicamycin is used at an art recognized toxic level (page 199, col. 2, paragraph 1):

"Since a feature of tunicamycin toxicity in animals impaired permeability of brain microvessels an important question whether tunicamycin has a direct effect on microvessels in vivo and if so whether glycoprotein components on the tight junctions are specifically altered".

It is clear from this citation that Tiganis was not wholly referring that use of tunicamycin in any capacity results in brain damage but merely reflecting on evidence seen in the prior art when tunicamycin is administered at a toxic level; moreover, since the prior art has recognized the levels at which tunicamycin toxicity occurs, one of skill in the art would know what dosage levels would be inappropriate.

For the above reasons it is believed that the rejections should be sustained.

(11) Related Proceeding(s) Appendix

No decision rendered by a court or the Board is identified by the examiner in the Related Appeals and Interferences section of this examiner's answer.

For the above reasons, it is believed that the rejections should be sustained.


Respectfully submitted,



Ganapathy Krishnan

June 14, 2006

Conferees:


Shaojia Anna Jiang
Supervisory Patent Examiner
Art Unit 1623
James O. Wilson
Supervisory Patent Examiner
Art Unit 1624

GREENBLUM & BERNSTEIN, P.L.C.
1941 ROLAND CLARK PLACE
RESTON, VA 20191.